Trial Profile
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Exemestane; Goserelin
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Male breast cancer
- Focus Registrational; Therapeutic Use
- 15 Aug 2023 Planned End Date changed from 28 Oct 2028 to 14 Jun 2024.
- 18 Mar 2023 Planned End Date changed from 23 Oct 2028 to 28 Oct 2028.
- 18 Oct 2021 Planned End Date changed from 14 Jan 2021 to 23 Oct 2028.